Lupin gains(#overlap 2020-04-04 18:54:16) after Florida facility gets(#before 2020-04-04 18:54:16) EIR from USFDA .
2020-04-04 18:54:16 +00:00 .
Lupin rose(#before 2020-04-04 18:54:16) 2.92 % to Rs 562.95 after Lupin said(#before 2020-04-04 18:54:16) its Inhalation Research Center in Florida received(#before 2020-04-04 18:54:16) Establishment Inspection Report ( EIR ) from the US drug regulator .
Lupin on Monday ( 30 March ) announced(#included Monday ( 30 March) the receipt of the Establishment Inspection Report ( EIR ) from the US Food and Drug Administration ( USFDA ) for its Inhalation Research Center in Florida .
its Inhalation Research Center in Florida was inspected(#included 2015-08) by the US Food and Drug Administration ( USFDA ) , between 19th and 26th February 2020 , on behalf of the U.K. Medicines and Healthcare products Regulatory Agency ( MHRA ) for Lupin generic Fostair application to the US Food and Drug Administration ( USFDA ) .
Lupin Inhalation Research Center at Coral Springs in Florida , USA , inaugurated(#included 2015-08) in August 2015 , focuses(#included 2015-08) on research and development(#included 2015-08) of respiratoryproducts for the treatment of asthma , chronic obstructive pulmonary diseases and other respiratory ailments .
Commenting(#before 2020-04-04 18:54:16) on the receipt of the Establishment Inspection Report ( EIR ) from the US Food and Drug Administration ( USFDA ) , Vinita Gupta , CEO , Lupinsaid , its Inhalation Research Center in Florida was established(#before 2020-04-04 18:54:16) to develop(#before 2020-04-04 18:54:16) quality respiratory products to benefit(#before 2020-04-04 18:54:16) patients across USA and other advanced markets .
the receipt of the Establishment Inspection Report ( EIR ) from the US Food and Drug Administration ( USFDA ) validates(#before 2020-04-04 18:54:16) our commitment towards ensuring(#overlap 2020-04-04 18:54:16) the highest levels of quality and CGMP compliance(#overlap 2020-04-04 18:54:16) at all our sites .
our are grateful for the U.S. FDA 's confidence(#before 2020-04-04 18:54:16) in our team during this critical juncture in the fight(#overlap 2020-04-04 18:54:16) against COVID-19 , when it has become(#before 2020-04-04 18:54:16) imperative that our focus(#after 2020-04-04 18:54:16) onbringinghigh quality respiratory products to market(#after 2020-04-04 18:54:16) .
Meanwhile , on Friday ( 27 March ) , Lupin and Mylan N.V. announced(#included 2020-04-03) that the European Medicines Agency 's Committee for Medicinal Products for Human Use ( CHMP ) has adopted(#included 2020-04-03) a positive opinion recommending the approval of Nepexto , a biosimilar to Enbrel ( etanercept ) , for all indications of the reference product including rheumatoid arthritis , juvenile idiopathic arthritis , psoriatic arthritis , axial spondyloarthritis ( including ankylosing spondylitis and non - radiographic axial spondyloarthritis ) , plaque psoriasis and paediatric plaque psoriasis .
a positive opinion recommending the approval of Nepexto , a biosimilar to Enbrel ( etanercept ) , will now be considered(#included PRESENT_REF) by the European Commission ( EC ) .
Once approved(#before 2020-04-04 18:54:16) , the European Commission ( EC ) will grant(#after 2020-04-04 18:54:16) a centralized marketing authorization for member countries of the EU .
The decision(#included 2020-05) on the approval of Nepexto , a biosimilar to Enbrel ( etanercept ) is expected(#included 2020-05) in May 2020 .
Nepexto , a biosimilar to Enbrel ( etanercept ) had(#included 2015-08) sales of approximately $ 9.6 billion globally for the 12 months ending(#included 2020-05) December 2019 , according to IQVIA .
In June 2018 , Lupin and Mylan N.V. announced(#included 2018-06) a collaboration(#included 2018-06) to commercialize(#included 2018-06) a biosimilar to etanercept in several global markets .
On a consolidated(#included 2015-08) basis , Lupin reported(#included Q3 December 2019) a net loss(#included Q3 December 2019) of Rs 835 crore in Q3 December 2019 as against a net loss(#included 2020-05) of Rs 151.75 crore in Q3 December 2018 .
Net sales declined(#included Q3 December 2019) 2.75 % to Rs 3,716.09 crore in Q3 December 2019 over Q3 December 2018 .
Lupin is engaged(#before 2020-04-04 18:54:16) in producing(#before 2020-04-04 18:54:16) , developing(#before 2020-04-04 18:54:16) and marketing(#included 2018-06) a range of branded(#before 2020-04-04 18:54:16) and generic formulations , biotechnology products and active pharmaceutical ingredients ( APIs ) across the world .
Lupin offers(#overlap 2020-04-04 18:54:16) products in the cardiovascular , diabetology , asthma , pediatrics , central nervous system , gastro - intestinal , anti - infectives and non - steroidal anti - inflammatory drug therapy areas .
